(Journal Article): Improved glycemic control with no weight in-crease in patients with type 2 diabetes after once-daily treat-ment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR
IN:
Diabetes Care
2004; 27(6):1335-1342
Impact Factor(s) of Diabetes Care: 7.071 (2004), 7.501 (2003), 5.477 (2002), 5.404 (2001)
ABSTRACT: OBJECTIVE: Liraglutide is a long-acting glucagon-like peptide 1 analog designed for once daily injection. This study assessed the efficacy and safety of liraglutide after 12 weeks ... Click HERE for details
|
||